** Shares of drugmaker Bristol Myers Squibb BMY.N fall 6.8% to $46.41 after the bell
** BMY says its drug Cobenfy failed to show to statistically significant difference compared to placebo in a late-stage trial studying it as an add-on treatment for schizophrenia
** In September, the U.S. Food and Drug Administration approved the drug, making it the first new type of antipsychotic medicine in decades
** BMY had obtained drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics in 2023
** So far this year, BMY stock down about 12%, as of last close
(Reporting by Savyata Mishra in Bengaluru)
((Savyata.Mishra@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。